Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according ...

The FDA approved protocol updates to a tasquinimod trial in myelofibrosis, allowing broader enrollment and combination use ...

A new study from The University of Texas MD Anderson Cancer Center has found that treating prostate cancer early, before it spreads widely, can make a big difference. The research, published in The ...

The University of Texas MD Anderson Cancer Center is pleased to announce the national launch of an innovative new science exhibition, showcasing the groundbreaking research, technologies and promising ...